Gaffin David Joseph sold $88K of ALKS
Gaffin David Joseph (EVP, CLO, Alkermes, Inc.) sold 2,034 shares of Alkermes plc. (ALKS) at $43.05 on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This disclosure mainly informs positioning/sentiment rather than changing Alkermes’ fundamentals.
Market read
A modest sentiment datapoint for ALKS, but unlikely to drive a durable repricing without additional company-specific catalysts.
What to watch
The filing does not indicate intent or new information about Alkermes fundamentals; traders should avoid extrapolating from a single small sale without corroborating catalysts.
Background
SEC Form 4 reports insider transactions by company officers/directors/10% owners; 10b5-1 plans are pre-scheduled trades intended to reduce timing-based inference.
Ticker impact
Alkermes disclosed an officer open-market sale of 2,034 shares (~$87.6K) under a pre-arranged 10b5-1 plan on 2026-06-04.
Low likelihood of a sustained price move; any reaction is likely brief unless accompanied by other news.
The filing is an ownership-change disclosure (not earnings/M&A/regulatory/drug data). The sale is explicitly under a pre-arranged 10b5-1 plan, which reduces interpretive signal.
Market effects
Minimal; this is company-specific insider activity with no stated operational/clinical/regulatory change.
None indicated beyond potential small sentiment effect in US biotech/biopharma trading.
None indicated.
Counterpoint
Because the transaction is under a 10b5-1 plan, the market may overreact; price impact could be negligible once traders recognize the pre-arranged nature.
Key entities
- issuerAlkermes plc
Subject of the Form 4 insider transaction; EVP sold shares under a 10b5-1 plan.
- insiderGaffin David Joseph
EVP, CLO at Alkermes; executed an open-market sale of 2,034 shares.
